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Nivolumab was approved as a new agent for advanced renal cell carcinoma (RCC) in Japan on
September 2016. Nivolumab is an immune checkpoint inhibitor that activates the cytotoxic immune
response and has exerted antitumor effects in a mechanism different from other available molecular targeted
agents. Therefore, its response pattern, efficacy and adverse events are different from those of the molecular
targeted agents for RCC. Here, we report our initial clinical experience with nivolumab. From December
2016 to September 2017, we applied nivolumab to 7 patients with metastatic RCC. The most common
metastatic site was the lungs, followed by lymph nodes, bones and brain. According to the immune-related
response criteria, the efficacy was stable disease in 2 patients and progressive disease in 5 patients. In 5 cases
with multiple metastases, responses differed with the site of metastasis. The response was best in lung
metastasis and worst in brain metastasis. Six cases had minor adverse events. In two cases, we
discontinued administration of nivolumab temporarily. The patients recovered completely and we
considered nivolumab effective and safe for treatment of metastatic RCC.
(Hinyokika Kiyo 64 : 383-389, 2018 DOI : 10.14989/ActaUrolJap_64_10_383)
















grammed cell death-1）に対するヒト IgG4 モノクロー
















応を判断した．投与は 3 mg/kg を 2週ごとに行った．















































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. The sites of metastases of renal cell carci-
noma and the efficacy of nivolumab
Case Lung LN Bone Brain Other*
1 CR PR§ PR§ PD PD
2 SD ― ― PD PD
3 PD PD PD PD PD
4 PR PD ― PD SD
5 SD ― ― ― ―
6 SD PD SD ― ―
7 ― ― ― ― SD†
CR : complete response, PR : partial response, SD : stable
disease, PD : progressive disease, LN : lymph node. § : the
lesions were treated with nivolumab and radiation. † :
pseudo progression (the lesion shrunk in size after the lesion
had progressed once.). * : other metastatic lesions included
liver, skin, adrenal and pleura.
全例，初回投与は入院で行い， 2クール目以降は外来
で施行した． 1∼ 2カ月ごとに画像検査を行い，治療












症例はなく，不変（SD） 2 例，増悪（PD） 5 例で
あった．治療効果を部位ごとにまとめたものを Table







（定位照射 3例，全脳照射 1例）を行い， 1例で病勢
コントロールが可能であったが， 3例は再増大もしく
は進行性病変であった．





症例 #7 においては副腎転移巣がニボルマブ開始 3
コース後に一過性に増大を認めたが，開始後 7コース
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Fig. 1. Chest CT of patient #1 and #4. a) Patient #1 : before nivolumab was started, b) Patient #1 : lung metastases
were reduced in size after 2 courses of nivolumab, c) Patient #1 at the presentation of brain metastasis after 7
courses, d) Patient #4 : before nivolumab was started, e) Patient #4 : lung metastases were reduced in size after 6
courses of nivolumab, f) Patient #4 : brain metastasis appeared after 9 courses of nivolumab.
泌62,08,0◆-2
Fig. 2. Abdominal CT : a) right adrenal metastasis (arrow) before nivolumab was started, b) pseudo progression of
adrenal metastasis after 2 courses of nivolumab, c) shrinkage of right adrenal metastasis after 7 courses of
nivolumab.
泌62,08,0◆-3
Fig. 3. CT of #1 patient. a) CT before nivolumab was started shows right clavicle metastasis (arrow), b) CT after 3
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Fig. 4. a) Radiotherapy targeted right ilium and thighbone, b) and d) CT before the radiation shows right ilium and
thighbone (arrows) and left ilium metastases (arrow head), c) abdominal CT after the radiation (30 Gy/10 fr)
shows the reduction of tumor size in right thighbone (arrows), e) CT reveals left ilium metastasis (arrow head)
also reduced out of radiation-targeted area (abscopal effect).
が著明に増大したことから偽性増悪（pseudo progres-









各症例の有害事象について Table 3 に示す．計 6症
例10種類の有害事象を認め，grade 1∼2 が大半を占め
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Table 3. Adverse events of nivolumab treatment
Case Adverse event Gradea) Course Therapyb) Nivolumab withdrawalc)
1 Herpes zoster 2 10 Oral medicine N
2 Bacterial pneumonia 2 1 Antibiotic therapy Y
3 Diarrhea 2 3 Oral medicine N
4 Wheal 1 1 Observed N
4 Febrile 1 1 Observed N
4 Fatigue 1 2 Observed N
5 Bacterial pneumonia 2 1 Antibiotic therapy N
6 Psoriasis 1 1 Observed N
6 Decreased appetite 1 1 Observed N
6 Diarrhea 3 10 Oral medicine Y
a) Grade was classified by CTCAE4.0, b) no case needed steroid therapy, c)“Y”means nivolumab was











































が発現する pseudo progression13) が時に生じることが
知られている．他の免疫チェックポイント阻害薬であ
るペンブロリズマブのメラノーマへの治療成績では
6.7％に pseudo progression が報告されており，発生頻
度としては比較的少ない14)．今回この pseudo progres-
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